Oncodesign Precision Medicine: Report of the annual General Meeting of 30 May 2023
31 5월 2023 - 1:00AM
Business Wire
Nomination of Florence Dupré as a member of
the Board of Directors
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63;
Mnemonic: ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancer, today announced the results of its annual General Meeting,
which took place at 2:30pm on 30 May 2023, and the nomination of
Florence Dupré as a member of its Board of Directors.
Karine Lignel, Deputy CEO and COO, said: "I am very
pleased with the way that OPM's first annual General Meeting since
its IPO in October 2022 took place. This is an important time of
year when the Management, the Board of Directors and our
shareholders gather to take decisions that will guide our future
development projects. I am also particularly delighted that
Florence Dupré has joined our Board of Directors. As an experienced
manager in the heart of the French healthcare ecosystem, she
represents a real asset for our team and for the Company,
particularly in supporting our CSR policy."
- Nomination of Florence Dupré to the Board of
Directors
Florence Dupré, a leading healthcare executive with over 28
years' experience in the sector, joins the OPM team as a member of
the Board of Directors.
Florence Dupré holds a Master's degree in biology and
biochemistry from the École Normale Supérieure ULM, as well as a
Master's degree in marketing management from ESSEC. After
contributing to several product launches for international
pharmaceutical companies, she began entrepreneurial activities by
setting up the French subsidiaries of BioAlliance Pharma (now
Onxeo) and Vifor Pharma. Then, she joined AbbVie, where she held
international responsibilities for sales and transformation.
Following this, she became President of the French subsidiary of
Medtronic, a world leader in healthcare technologies, at a time
when the group was changing its business model during the COVID-19
pandemic. During her 2.5-year term, she focused on operational
efficiency, customer service quality and the subsidiary's
visibility within the ecosystem. Florence Dupré was also a member
of the Board of Directors and Executive Committee of the Syndicat
National des Technologies Médicales (SNITEM), and a member of the
Management Board of the Fondation Université Rennes. In 2022, her
article entitled "Diriger, c'est faire grandir" ("Leading is
growing up") was published in Les Echos, and she received the "Coup
de cœur" award from the Expressions de France Association for her
commitment to inclusion in the workplace. In 2023, Le Figaro
devoted a profile to her entitled "L'entreprise est aussi un
laboratoire citoyen", and she was highlighted by the R&B et
Associés agency as one of ten exceptional women on International
Women's Rights Day. She is also the godmother of the 15th promotion
of ESSEC's Women Board Ready programme.
Florence Dupré commented: "I am very honoured and proud
to be able to contribute to OPM's development as a Board member.
The core business of this biotech and the quality of its teams
illustrate how artificial intelligence and digital technology are
revolutionizing the whole value chain of the healthcare industry,
starting with the discovery and development of new targets.”
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers. OPM's innovative technologies are (i)
OncoSNIPER for the selection of therapeutic targets using
artificial intelligence; (ii) Nanocyclix® for the design and
selection of macrocyclic small molecule kinase inhibitors and (iii)
Theranostics for the design and selection of radiolabeled
biological molecules for systemic radiotherapy. From these
technologies, OPM has built a portfolio of therapeutic products. A
first drug candidate based on the Nanocyclix® technology entered
the clinical phase in 2022, in partnership with SERVIER (which
exercised its option for an exclusive worldwide license on the
program) to treat Parkinson's disease. ODS 101 is OPM's second
candidate to enter the clinic, in the treatment of chronic
immuno-inflammatory diseases. Finally, OPM is also collaborating
with Servier to discover new therapeutic targets for the treatment
of pancreatic adenocarcinoma based on its OncoSNIPER technology. In
addition, OPM is seeking a partner for Florepizol, a radiotracer
specific for the mutated EGFR target, which has successfully
completed Phase 1. Two projects are in early partnership phase with
TIUMBIO (pulmonary fibrosis) and SEngine in oncology. Finally, OPM
has a significant portfolio of early-stage projects with
Nanocyclix® and Theranostics in oncology. With this portfolio of
molecules and diversified therapeutic targets, OPM's mission is to
discover effective therapies to treat resistant and advanced
cancers. Based in Dijon, at the heart of the university and
hospital cluster, OPM has 25 employees.
More info at: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005498/en/
OPM Philippe Genne Chairman and Chief Executive Officer
Tel: +33 (0)3 80 78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024